Skip to content

the Effects of GnRHa Add up to Routine Luteal Phase Support on Frozen Embryo Implantation in Frozen Embryo Transfer .

Implantation in Frozen Embryo Transfer

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02655146
Enrollment
700
Registered
2016-01-13
Start date
2015-12-31
Completion date
2017-03-31
Last updated
2016-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

Frozen embryo transfer,luteal support, GnRHa

Brief summary

The aim of the present prospective randomized controlled study was to determine the effects of GnRHa add up to routine luteal phase support on frozen embryo implantation in frozen embryo transfer (FET).

Detailed description

Some recent data have suggested a beneficial effect of GnRHa administered in the luteal phase on the outcome of assisted reproduction techniques. In those studies, the dose and administration time of GnRHa are inconsistent. Single administration on third day after embryo transfer and multiple dose injection during luteal phase are the most common way. The GnRHa included Triptorelin 0.1mg, Leuprorelin 1mg and Buserelin 600ug et al. The exact underlying mechanism is still not clear, although it has been hypothesized that GnRH agonist either supports the corpus luteum function by inducing LH secretion by the pituitary gonadotrophin cells or stimulates the endometrium GnRH receptors . Tesarik et al.postulated a direct effect of GnRH agonist on the embryo, evidenced by increased β-HCG secretion. Currently, available data suggest that inadvertent administration of a GnRH agonist during a conception cycle is not accompanied by an increased risk of birth defects. On the basis of the currently strong available evidence, it appears that GnRH agonist supplementation during luteal phase significantly improve the outcome of ART treatment. Most of the former researches focused only on fresh embryo transfer in IVF/ICSI cycles. In one prospective controlled study, a single dose of Triptorelin 0.1mg was administrated 6 days after ICSI in oocyte donor cycles and the implantation rate was improved significantly.GnRH agonist administration at the time of implantation enhances embryo developmental potential, probably by a direct effect on the embryo.

Interventions

DRUGtriptorelin 0.1

a single dose of decapeptyl 0.1 s.c. on the 3rd day of embryo transfer with routine luteal phase support.

DRUGE2

Patients will be on the Progynova tablets 4-10mg daily at least 14 days.

DRUGProgesterone

After ultrasound and hormorne tests, progesterone 100mg intramuscular injection is allocated with Progynova.

DRUGtriptorelin 3.75mg

as a pretreatment of E2 in some subjects with a fail history of hormonal artificially endometrium preparing.

Sponsors

Chong Qing Reproducive and Genetic Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 37 Years
Healthy volunteers
No

Inclusion criteria

* infertile women with frozen thawed embryo transfer after HRT endometrial preparation. * more than 20 years old, and less than 37 years old. * BMI less than 28kg/m2. * more than 1 transplantable embryo after thawing. * patients should sign the informed consent and have the willing to follow up.

Exclusion criteria

* uterine malformation * diameter of intramural myoma more than 3cm * the thickness of endometrium less than 7mm on the progesterone supportive day.

Design outcomes

Primary

MeasureTime frame
implantation rate5 weeks

Secondary

MeasureTime frame
clinical pregancy rate9 weeks

Countries

China

Contacts

Primary ContactXIU Luo, master
luoxiu1982@163.com008602363839850

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026